Recent results from Roche’s Phase III IMpower 150 lung cancer study have demonstrated that atezolizumab, bevacizumab, chemotherapy combination doubles 12-month PFS.
Browsing: lung cancer
The EU Position Statement on Lung Cancer Screening (EUPS) has presented evidence to address successful implementation of lung cancer screening programs for European countries.
Would you like to find out the key facts about non-small-cell lung cancer? We have…
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Over the coming weeks on Oncology Central we will be highlighting the latest advancements in lung cancer. Join us as we look explore key issues and current understanding in the diagnosis, staging and treatment of the disease by exploring all our content below.
What is the potential clinical significance of the results of the FLAURA trial presented at ESMO? Find out in our exclusive interview.
Listen to this podcast to discover more about CheckMate-153 study, data from which was presented at this years 2017 ESMO Congress (8–12th September, Madrid, Spain).
A recent clinical trial presents new data indicating durvalumab improves progression-free survival in patients with stage III non-small-cell lung cancer (NSCLC).
A study has indicated that patients with advanced inoperable stage 3 lung cancer can benefit from an improved rate of survival when undergoing concurrent chemotherapy and proton therapy.
Induction of receptor tyrosine kinase signaling by sera isolated from patients with lung adenocarcinoma
Available to view on demand
Learn about a study that was accomplished as a means to explore the hypothesis that circulating concentrations of decoy receptors and/or ligands, as well as disease-specific ligand degradation all regulate RTK signaling in vivo.